ClinicalTrials.gg
WithdrawnNCT07111013NGL-Long TermUpdated Dec 10, 2025

A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease

A Phase 3 interventional study of Lifitegrast/perfluorohexyloctane (PFHO) in Dry Eye Disease, sponsored by Bausch & Lomb Incorporated. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-10.

Sponsored by Bausch & Lomb Incorporated (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Business Decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing lifitegrast in Dry Eye Syndromes — 2 open to participants now, 2 under way, none of them phase 3. lifitegrast · Dry Eye Syndromes.

Enrollment
18th of 22
0 · median 38
Started
2025
with 2 others
Phase 3
5 of 22
none open now
Registered
19th of 22
by date
Lead sponsor
2 of 22
Bausch & Lomb Incorporated

Among the 22 studies testing lifitegrast in Dry Eye Syndromes, this one is the 18th largest by enrollment, is one of 3 that started in 2025, is one of 5 in phase 3, and was the 19th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

2 of the 22 studies testing lifitegrast in Dry Eye Syndromes are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About lifitegrast

lifitegrast: first FDA approval 2016 (XIIDRA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing lifitegrast in Dry Eye Syndromes, or all of them as a file.
02

Study summary

A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease

03

Conditions studied

  • Dry Eye Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

This study will include subjects who meet all of the following inclusion criteria:

  1. Voluntarily provide written
  2. Completed Study BL-RX01-OPUSNG-1201 and:

    1. Were compliant with BL-RX01-OPUSNG-1201 trial procedures and study drug use
    2. Had no important protocol deviations
    3. Had no ongoing adverse events (AEs)
  3. Are able and willing to follow instructions, including participation in all trial assessments and visits

Exclusion criteria

Exclusion Criteria:

This study will exclude subjects who meet any of the following exclusion criteria (Note: Ocular exclusion criteria are relevant to both eyes, such that meeting a criterion in either eye excludes the subject from the study):

  1. Have best-corrected visual acuity (BCVA) of 0.7 logMAR or worse (50 Early Treatment Diabetic Retinopathy Study [ETDRS] letters; Snellen equivalent score of 20/100 or worse) at Visit 1 (Screening/Baseline)
  2. Have any (CS) ocular surface slit-lamp findings and/or in the opinion of the Investigator have any findings that may interfere with trial parameters
  3. Any concurrent condition, concomitant treatment, or situation which, in the Investigator's opinion, may put the subject at significant risk, confound study results, or interfere with their participation in the trial
  4. Planned contact lens use during the trial
  5. Planned ocular and/or lid surgeries during the trial
  6. Unable or unwilling to avoid all topical dry eye treatments (except for study drug) during the first 4 weeks of participation
  7. Any non-drug therapies affecting meibomian glands such as LipiFlow® and Intense Pulse Light during the trial
  8. Participation in any drug or device study other than BL RX01-OPUSNG-1201 or BL-RX01-NGL-1301-LTS
  9. Any female who is nursing, lactating, pregnant, planning a pregnancy, or has a positive urine pregnancy test at Visit 1 (Screening/Baseline)
  10. Any female of (FOCBP) who is unwilling to agree to:

    1. Have a urine pregnancy testing performed at Visit 1 (Screening/Baseline)
    2. Use at least 1 medically acceptable form of for at least 14 days prior to the first dose of study drug, throughout the study duration, and for 1 month after the last dose of study drug Note: FOCBPs include all females who have experienced menarche and have not experienced menopause (as defined by amenorrhea for greater than 12 consecutive months) or have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy)

    Note: Acceptable forms of birth control include:

    • Mechanical (spermicide in conjunction with a barrier such as a diaphragm or condom)
    • Hormonal contraceptive (oral, injectable, implantable, or transdermal)
    • Intrauterine device
    • Surgical sterilization of male partner at least 3 months prior to the first dose of study drug Note: For non-sexually active female subjects, abstinence may be regarded as an adequate method of birth control when this is in line with the preferred and usual lifestyle of the subject; however, if the subject becomes sexually active during the trial, she must agree to use adequate birth control as defined above for the remainder of the trial
  11. Any male who is unwilling to agree to use at least 1 medically acceptable form of birth control with female partner (FOCBP)

Note: Acceptable forms of birth control include:

  • True abstinence (when this is in line with the preferred and usual lifestyle of the subject), or
  • Vasectomy at least 3 months prior to the first dose of study drug Without a vasectomy, must use condoms with spermicidal foam, gel, film, cream, suppository at least 14 days prior to the first dose of study drug, throughout the study duration, and for 1 month after the last dose of the study drug
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Lifitegrast/perfluorohexyloctane (PFHO) fixed-dose combination (FDC) (5%/95%)

    Lifitegrast/perfluorohexyloctane (PFHO) fixed-dose combination (FDC) (5%/95%) packaged in multidose bottles, with 1 topical ocular drop instilled in both eyes (OU) twice daily (BID)

    Drug: Lifitegrast/perfluorohexyloctane (PFHO)

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment Emergent Adverse Events

    Time frame: Assessed for 12 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2025; primary completion for Apr 2027, 16 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2025
First posted
Aug 8, 2025
StartEst.
Dec 2025
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
Dec 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07111013
Responsible party
Sponsor
First posted
Aug 8, 2025
Start date
Dec 2025 (estimated)
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Dec 10, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lifitegrast · Perfluorohexyloctane

Start the discussion